Fenwick represented Earli, a bioengineering firm which developed a new platform technology that will allow clinicians to exactly locate early cancers so they can be treated, in its $40 million Series A financing. The financing was led by Khosla Ventures, along with Perceptive Advisors, Casdin Capital, Andreessen Horowitz, Sands Capital, and top individuals including Midas List investors Jim Breyer/Breyer Capital and Rahul Mehta, Goldman Sachs’s former CFO and CIO R. Martin Chavez, and biomedical device entrepreneur Shlomo Ben-Haim.
Using technology licensed from Stanford University, Earli is creating a new platform technology called a “Synthetic Biopsy,” which uses genetic constructs to force cancer to produce biomarkers not normally expressed in the human body. The Synthetic Biopsy locates early cancer, which then enables actionable therapies. More information can be obtained from Earli’s announcement.
The Fenwick transaction team included corporate partners Mark Stevens and Matthew Rossiter, as well as associates Noah Johnson and Joanna Xu.